TB: The Leading Infectious Disease Killer and Its Rising Threat

The grave concern over tuberculosis (TB), the top infectious disease killer, has intensified with a new study highlighting potential consequences of reduced foreign aid from the U.S.

A Vietnamese doctor reviews a chest X-ray of a patient resistant to tuberculosis medication at the National Lung Hospital in Hanoi. TB continues to claim more lives annually than any other infectious disease. Recent projections suggest that if U.S. foreign aid to TB initiatives is curtailed, the situation may become dire.

"As long as a person is alive and breathing, they're at risk anywhere globally," asserts Dr. Lucicia Ditiu, underscoring the persistent threat of TB.

Tuberculosis, often misperceived as a bygone illness, presently causes about 1.2 million deaths per year across the globe. According to freshly published research, reductions in U.S. foreign aid under the Trump administration could lead to a significant increase in these figures. Estimates suggest that up to 10 million new TB cases could emerge in the most vulnerable countries over the forthcoming five years with increased fatalities.

Even in an optimistic scenario where financial support is rapidly reinstated, researchers project an additional half-million TB cases and nearly 100,000 deaths within the next decade.

The impact of these funding reductions is most pronounced in regions least able to substitute lost resources. Although their predictions carry some uncertainty, the solid methodologies employed underline how delays exacerbate public health outcomes.

U.S. Aid and Global TB Control

A substantive portion of TB programs worldwide is financially backed by the United States. As of 2024, the U.S. provided over 55% of the external international support required for TB control, with significant funds coming through USAID. This funding aids every step from screening, diagnosis, treatment to patient support throughout the lengthy treatment process.

In Bangladesh, USAID's contributions of over $100 million in the last decade have led to a 36% reduction in TB deaths since 2015. Still, challenges remain with 20% of TB cases undiagnosed, leaving a large gap in treatment.

Public health expert Tasmieh Selim, affiliated with BRAC non-profit, began a USAID-funded initiative to address these issues. However, after initial work commenced, a halt was imposed due to the funding freeze, showcasing the impactful absence of financial backing.

The tangible effects of funding scarcity are already becoming apparent, especially in Africa and Asia, where diagnoses and treatments have markedly decreased by up to 15% in some areas.

Determining the precise death toll due to aid withdrawal challenges researchers, as exact figures on funding fluctuations and national response efforts remain elusive.

In a statement, the State Department noted that multiple countries continue to receive funds from U.S. taxpayers for critical TB interventions. Yet, specifics on the amounts and the extent of funding were withheld.

Estimating Future Impacts

Dr. Ditiu and her research team leveraged epidemiological data of TB and U.S. funding dynamics to predict consequences in 26 high-burden nations. With scenarios varying from swift recovery to persistent deficits, the researchers illustrated potential outcomes.

The most severe projection outlines over 10 million new TB cases and upwards of 2.2 million deaths through 2030. Even with immediate restoration of funds, an additional 100,000 fatalities are anticipated as undiagnosed cases grow.

Timely identification and treatment are crucial to curbing TB's spread, with untreated patients potentially infecting 15 to 20 others annually.

Interrupted treatment regimens pose another risk as they can lead to drug-resistant TB strains, significantly increasing the cost and complexity of treatment.

Despite uncertainties, the moderate scenario forecasts 268,000 additional deaths by 2030, encouraging concerted efforts to mitigate these grave outcomes.

This report aims to urge governments and donors alike to limit TB's growth and protect vulnerable and affluent populations equally in our interconnected global landscape.